Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

被引：1
|
作者：
Pemmaraju, Naveen
Carter, Bing Z.
Kantarjian, Hagop M.
Cortes, Jorge E.
Kadia, Tapan M.
Garcia-Manero, Guillermo
DiNardo, Courtney D.
Bose, Prithviraj
Pierce, Sherry
Zhou, Lingsha
Estrov, Zeev
Tuttle, Carla Kay
Salinas, Karina
Mak, Po Yee
Verstovsek, Srdan
机构：
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3105.3105
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3105
引用
收藏
页数：5
相关论文
共 50 条
  • [1] PHASE II STUDY OF LCL161, A SMAC MIMETIC, IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) OR POST-ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS (POST-ET MF
    Pemmaraju, N.
    Kantarjian, H.
    Cortes, J.
    Kadia, T.
    DiNardo, C.
    Estrov, Z.
    Pierce, S.
    Zhou, L.
    Salinas, K.
    Tuttle, C.
    Mak, P. Y.
    Carter, B. Z.
    Verstovsek, S.
    HAEMATOLOGICA, 2016, 101 : 95 - 95
  • [2] A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, John
    Sandy, Lonette
    Lu, Min
    Yoon, James
    Petersen, Bruce
    Zhang, David
    Ye, Fei
    Newsom, Carrie
    Najfeld, Vesna
    Hochman, Tsivia
    Goldberg, Judith D.
    Hoffman, Ronald
    LEUKEMIA RESEARCH, 2017, 53 : 13 - 19
  • [3] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [4] PHASE 1/2, DOSE-ESCALATION STUDY OF ORAL NS-018 IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF (POST-ET MF)
    Uno, T.
    Verstovsek, S.
    Mesa, R.
    Talpaz, M.
    Ritchie, E.
    Wadleigh, M.
    Odenike, O. M.
    Jamieson, C.
    Stein, B.
    HAEMATOLOGICA, 2015, 100 : 542 - 543
  • [5] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Barosi, G.
    Linardi, C.
    Ben Yehuda, D.
    Henrique Daumas Gabriel, A.
    Perez, J.
    Modi, A.
    Khan, M.
    Zweegman, S.
    Raymakers, R.
    Vianelli, N.
    Pakstyte, S.
    Willenbacher, W.
    Gisslinger, H.
    HAEMATOLOGICA, 2012, 97 : 321 - 321
  • [6] Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
    Gupta, Vikas
    Yacoub, Abdulraheem
    Verstovsek, Srdan
    Mesa, Ruben
    Harrison, Claire
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Deeg, H. Joachim
    Fazal, Salman
    Foltz, Lynda
    Mattison, Ryan J.
    Miller, Carole B.
    Parameswaran, Vinod
    Martin-Regueira, Patricia
    Hernandez, Christopher
    Wang, Jia
    Talpaz, Moshe
    BLOOD, 2022, 140 : 3935 - 3937
  • [7] COMPASSIONATE USE PROGRAM (CUP) WITH RUXOLITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Vargas, P.
    Karpovitch, X.
    Alvarado, M.
    Ovilla, R.
    Agreda, G.
    Guzman, P.
    Solis, J.
    Kassack, J.
    Silva, S.
    Zavala, S.
    Morales, J.
    Herrera, A.
    Reynoso, E.
    Rodriguez, M.
    Ruiz, G.
    Sobrevilla, P.
    Garcia, M.
    Aguilar, C.
    Morales, R.
    Barrera, E.
    Osuna, A.
    Carrillo, R.
    Silos, G.
    Vega, A.
    Cuin, S.
    Mora, M.
    Best, C.
    Murillo, E.
    Loarca, L.
    Perez, O.
    Salazar, J.
    Baez, E.
    Montemayor, J.
    Barrera, D.
    Garcia, J.
    Peraza, L.
    Baltazar, S.
    Iniguez, L.
    Oseguera, R.
    Nacho, K.
    Romero, T.
    HAEMATOLOGICA, 2013, 98 : 765 - 766
  • [8] An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
    Barosi, Giovanni
    Agarwal, Mohan
    Zweegman, Sonja
    Willenbacher, Wolfgang
    Pakstyte, Sima
    Raymakers, Reinier
    Cantoni, Nathan
    Modi, Ankur
    Khan, Mahmudul
    Perez, Jose Ricardo
    Hasselbalch, Hans
    Vargas Viveros, Jose Pablo
    Linardi, Camila C. G.
    Gisslinger, Heinz
    Daumas Gabriel, Adelmo Henrique
    Palandri, Francesca
    Lavie, David
    Harrison, Claire N.
    BLOOD, 2012, 120 (21)
  • [9] Primary myelofibrosis (PMF), post polycythernia vera myelotibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
    Mesa, Ruben A.
    Verstovsek, Srdan
    Cervantes, Francisco
    Barosi, Giovanni
    Reilly, John T.
    Dupriez, Brigitte
    Levine, Ross
    Le Bousse-Kerdiles, Marie-Caroline
    Wadleigh, Martha
    Campbell, Peter J.
    Silver, Richard T.
    Vannucchi, Alessandro M.
    Deeg, H. Joachim
    Gisslinger, Heinz
    Thomas, Deborah
    Odenike, Olatoyosi
    Solberg, Lawrence A.
    Gotlib, Jason
    Hexner, Elizabeth
    Nimer, Stephen D.
    Kantarjian, Hagop
    Orazi, Attilio
    Vardiman, James W.
    Thiele, Juergen
    Tefferi, Ayalew
    LEUKEMIA RESEARCH, 2007, 31 (06) : 737 - 740
  • [10] A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis
    DeAngelo, D. J.
    Tefferi, A.
    Mesa, R. A.
    Paley, C. S.
    Wadleigh, M.
    Snyder, D.
    Ondovik, M. S.
    Rine, J.
    Bhalla, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345